2021 CSCO临床指南:恶性淋巴瘤的诊断和治疗(英文版)

2021-06-30 中国临床肿瘤学会 Chin J Cancer Res . 2021 Jun 30

淋巴瘤是一组异质性疾病,主要分为两大类:霍奇金淋巴瘤(HL)和非霍奇金淋巴瘤(NHL)。据估计,中国每年有 75,400 例发病病例和 40,500 例死亡,其中 NHL 约占淋巴瘤负担的 90% (

中文标题:

2021 CSCO临床指南:恶性淋巴瘤的诊断和治疗(英文版)

英文标题:

Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for malignant lymphoma 2021 (English version)

发布机构:

中国临床肿瘤学会

发布日期:

2021-06-30

简要介绍:

淋巴瘤是一组异质性疾病,主要分为两大类:霍奇金淋巴瘤(HL)和非霍奇金淋巴瘤(NHL)。据估计,中国每年有 75,400 例发病病例和 40,500 例死亡,其中 NHL 约占淋巴瘤负担的 90% (1,2)。

相关资料下载:
[AttachmentFileName(sort=1, fileName=2021 CSCO临床指南:恶性淋巴瘤的诊断和治疗(英文版).pdf)] GetToolGuiderByIdResponse(projectId=1, id=57c621c0021a188c, title=2021 CSCO临床指南:恶性淋巴瘤的诊断和治疗(英文版), enTitle=Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for malignant lymphoma 2021 (English version), guiderFrom=Chin J Cancer Res . 2021 Jun 30, authorId=0, author=, summary=淋巴瘤是一组异质性疾病,主要分为两大类:霍奇金淋巴瘤(HL)和非霍奇金淋巴瘤(NHL)。据估计,中国每年有 75,400 例发病病例和 40,500 例死亡,其中 NHL 约占淋巴瘤负担的 90% (, cover=https://img.medsci.cn/2021731/1627739045572_2020535.jpg, journalId=0, articlesId=null, associationId=863, associationName=中国临床肿瘤学会, associationIntro=null, copyright=0, guiderPublishedTime=Wed Jun 30 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<div class="bp3-card bp3-elevation-0 result-block" style="color: #182026;"> <div class="bp3-collapse"> <div class="bp3-collapse-body bp3-fixed-positioning-containing-block" aria-hidden="false"> <div class="common-result"> <div class="general-result"> <p>淋巴瘤是一组异质性疾病,主要分为两大类:霍奇金淋巴瘤(HL)和非霍奇金淋巴瘤(NHL)。据估计,中国每年有 75,400 例发病病例和 40,500 例死亡,其中 NHL 约占淋巴瘤负担的 90% (1,2)。</p> </div> </div> </div> </div> </div>, tagList=[TagDto(tagId=25830, tagName=恶性淋巴瘤)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=21, categoryName=血液科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=25830, guiderKeyword=恶性淋巴瘤, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=7582, appHits=316, showAppHits=0, pcHits=1006, showPcHits=7263, likes=0, shares=22, comments=15, approvalStatus=1, publishedTime=Sat Jul 31 22:51:53 CST 2021, publishedTimeString=2021-06-30, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Sat Jul 31 21:44:58 CST 2021, updatedBy=2020535, updatedName=qiushida2, updatedTime=Fri Jan 05 20:42:11 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2021 CSCO临床指南:恶性淋巴瘤的诊断和治疗(英文版).pdf)])
2021 CSCO临床指南:恶性淋巴瘤的诊断和治疗(英文版).pdf
下载请点击:
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1206759, encodeId=9fbe1206e595e, content=请问有中文版吗, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211129/0708c577736746af9505e240c95bfe21/ed50f4e6812646388b702de78e18d26b.jpg, createdBy=e07e5430262, createdName=lexi Liao, createdTime=Tue Mar 29 00:39:54 CST 2022, time=2022-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1206758, encodeId=d7ba1206e58b6, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211129/0708c577736746af9505e240c95bfe21/ed50f4e6812646388b702de78e18d26b.jpg, createdBy=e07e5430262, createdName=lexi Liao, createdTime=Tue Mar 29 00:39:41 CST 2022, time=2022-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068084, encodeId=55a510680845f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ae65697887, createdName=ms2000001848149725, createdTime=Mon Nov 08 12:08:47 CST 2021, time=2021-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061548, encodeId=3fb410615485d, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210908/0a2513fcf13a40d0b7cefbf19efb116c/b9b7e818cc574d14a70c470375f4ccbd.jpg, createdBy=cc9f5598711, createdName=苏韵阑珊, createdTime=Mon Oct 18 17:47:31 CST 2021, time=2021-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056158, encodeId=e323105615846, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210515/7df7f6cbd49042d4a6329ae70c7ad7b5/b120f34b2f8846ae821ba21ac1adeab3.jpg, createdBy=24324873661, createdName=1903329706, createdTime=Wed Sep 29 16:33:33 CST 2021, time=2021-09-29, status=1, ipAttribution=)]
    2022-03-29 lexi Liao

    请问有中文版吗

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1206759, encodeId=9fbe1206e595e, content=请问有中文版吗, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211129/0708c577736746af9505e240c95bfe21/ed50f4e6812646388b702de78e18d26b.jpg, createdBy=e07e5430262, createdName=lexi Liao, createdTime=Tue Mar 29 00:39:54 CST 2022, time=2022-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1206758, encodeId=d7ba1206e58b6, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211129/0708c577736746af9505e240c95bfe21/ed50f4e6812646388b702de78e18d26b.jpg, createdBy=e07e5430262, createdName=lexi Liao, createdTime=Tue Mar 29 00:39:41 CST 2022, time=2022-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068084, encodeId=55a510680845f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ae65697887, createdName=ms2000001848149725, createdTime=Mon Nov 08 12:08:47 CST 2021, time=2021-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061548, encodeId=3fb410615485d, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210908/0a2513fcf13a40d0b7cefbf19efb116c/b9b7e818cc574d14a70c470375f4ccbd.jpg, createdBy=cc9f5598711, createdName=苏韵阑珊, createdTime=Mon Oct 18 17:47:31 CST 2021, time=2021-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056158, encodeId=e323105615846, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210515/7df7f6cbd49042d4a6329ae70c7ad7b5/b120f34b2f8846ae821ba21ac1adeab3.jpg, createdBy=24324873661, createdName=1903329706, createdTime=Wed Sep 29 16:33:33 CST 2021, time=2021-09-29, status=1, ipAttribution=)]
    2022-03-29 lexi Liao

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1206759, encodeId=9fbe1206e595e, content=请问有中文版吗, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211129/0708c577736746af9505e240c95bfe21/ed50f4e6812646388b702de78e18d26b.jpg, createdBy=e07e5430262, createdName=lexi Liao, createdTime=Tue Mar 29 00:39:54 CST 2022, time=2022-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1206758, encodeId=d7ba1206e58b6, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211129/0708c577736746af9505e240c95bfe21/ed50f4e6812646388b702de78e18d26b.jpg, createdBy=e07e5430262, createdName=lexi Liao, createdTime=Tue Mar 29 00:39:41 CST 2022, time=2022-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068084, encodeId=55a510680845f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ae65697887, createdName=ms2000001848149725, createdTime=Mon Nov 08 12:08:47 CST 2021, time=2021-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061548, encodeId=3fb410615485d, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210908/0a2513fcf13a40d0b7cefbf19efb116c/b9b7e818cc574d14a70c470375f4ccbd.jpg, createdBy=cc9f5598711, createdName=苏韵阑珊, createdTime=Mon Oct 18 17:47:31 CST 2021, time=2021-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056158, encodeId=e323105615846, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210515/7df7f6cbd49042d4a6329ae70c7ad7b5/b120f34b2f8846ae821ba21ac1adeab3.jpg, createdBy=24324873661, createdName=1903329706, createdTime=Wed Sep 29 16:33:33 CST 2021, time=2021-09-29, status=1, ipAttribution=)]
    2021-11-08 ms2000001848149725

    学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1206759, encodeId=9fbe1206e595e, content=请问有中文版吗, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211129/0708c577736746af9505e240c95bfe21/ed50f4e6812646388b702de78e18d26b.jpg, createdBy=e07e5430262, createdName=lexi Liao, createdTime=Tue Mar 29 00:39:54 CST 2022, time=2022-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1206758, encodeId=d7ba1206e58b6, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211129/0708c577736746af9505e240c95bfe21/ed50f4e6812646388b702de78e18d26b.jpg, createdBy=e07e5430262, createdName=lexi Liao, createdTime=Tue Mar 29 00:39:41 CST 2022, time=2022-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068084, encodeId=55a510680845f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ae65697887, createdName=ms2000001848149725, createdTime=Mon Nov 08 12:08:47 CST 2021, time=2021-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061548, encodeId=3fb410615485d, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210908/0a2513fcf13a40d0b7cefbf19efb116c/b9b7e818cc574d14a70c470375f4ccbd.jpg, createdBy=cc9f5598711, createdName=苏韵阑珊, createdTime=Mon Oct 18 17:47:31 CST 2021, time=2021-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056158, encodeId=e323105615846, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210515/7df7f6cbd49042d4a6329ae70c7ad7b5/b120f34b2f8846ae821ba21ac1adeab3.jpg, createdBy=24324873661, createdName=1903329706, createdTime=Wed Sep 29 16:33:33 CST 2021, time=2021-09-29, status=1, ipAttribution=)]
    2021-10-18 苏韵阑珊

    学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1206759, encodeId=9fbe1206e595e, content=请问有中文版吗, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211129/0708c577736746af9505e240c95bfe21/ed50f4e6812646388b702de78e18d26b.jpg, createdBy=e07e5430262, createdName=lexi Liao, createdTime=Tue Mar 29 00:39:54 CST 2022, time=2022-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1206758, encodeId=d7ba1206e58b6, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211129/0708c577736746af9505e240c95bfe21/ed50f4e6812646388b702de78e18d26b.jpg, createdBy=e07e5430262, createdName=lexi Liao, createdTime=Tue Mar 29 00:39:41 CST 2022, time=2022-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068084, encodeId=55a510680845f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ae65697887, createdName=ms2000001848149725, createdTime=Mon Nov 08 12:08:47 CST 2021, time=2021-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061548, encodeId=3fb410615485d, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210908/0a2513fcf13a40d0b7cefbf19efb116c/b9b7e818cc574d14a70c470375f4ccbd.jpg, createdBy=cc9f5598711, createdName=苏韵阑珊, createdTime=Mon Oct 18 17:47:31 CST 2021, time=2021-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056158, encodeId=e323105615846, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210515/7df7f6cbd49042d4a6329ae70c7ad7b5/b120f34b2f8846ae821ba21ac1adeab3.jpg, createdBy=24324873661, createdName=1903329706, createdTime=Wed Sep 29 16:33:33 CST 2021, time=2021-09-29, status=1, ipAttribution=)]
    2021-09-29 1903329706

    学习了

    0

拓展阅读

2015 培门冬酶治疗急性淋巴细胞白血病和恶性淋巴瘤中国专家共识

中国临床肿瘤学会(CSCO,Chinese Society of Clinical Oncology) · 2015-12-30

2015 ESMO恶性淋巴瘤共识会议建议:成熟的B细胞淋巴瘤和慢性淋巴细胞白血病的预测工具

欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology) · 2015-06-20

长春碱类药物治疗恶性淋巴瘤中国专家共识(2017)

中国抗癌协会淋巴瘤专业委员会 · 2017-02-10